RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced data highlighting the significant morbidity and resource utilization associated with the current standard of care for the management of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. This analysis, entitled "Preemptive Therapy (PrT) for Cytomegalovirus (CMV) Post-hematopoietic Cell Transplantation (HCT) is Associated with Significant Morbidity and Resource Utilization," was presented at the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, September 9-12, San Francisco).
Morbidity and Resource Utilization Associated with Preemptive Therapy
Preemptive therapy is the initiation of antiviral therapy in the presence of viral infection. Chimerix's presentation highlighted adverse effects (AEs) experienced by patients who received preemptive therapy and were treated with currently available antiviral agents, including valganciclovir, ganciclovir, foscarnet and cidofovir.
A retrospective analysis of data from 71 patients who received preemptive treatment of CMV infection showed that the majority experienced at least one significant AE. These AEs included:
- Decreases in neutrophil counts, with some patients requiring granulocyte colony-stimulating factor, or G-CSF, to support neutrophil recovery;
- Other cytopenias, with some patients requiring transfusions;
- Renal impairment;
- Bacterial and fungal infections (including one patient death from sepsis);
- Seizures; and
- Fluid and electrolyte imbalances.
Of these patients, 18% had life-threatening AEs, including bacterial infections, cytopenias, and hemorrhages, and 23% had an AE that required hospitalization. W